Total receipts for the LLS segment during the three months ended Dec. 31 increased to $563 million from $455 million year over year.
Companywide revenue increased to $741 million from $613 million in the year-ago period, though 19 percent of that growth was the result of acquisitions, Thermo said. Unfavorable currency translation cost the company 4 percent in revenue growth, the firm said.
"We experienced very strong growth from our industrial markets, especially in commodity materials and environmental monitoring," President and CEO Marijn Dekkers said in a statement. "In addition, growth from our life sciences customers continued at a good pace."
R&D spending in the fourth quarter increased 9 percent to $38 million from $35 million year over year, Thermo said.
Tax benefits tied to a divestiture last year caused profit in the period to decline 54 percent to $56 million, or $.34 per basic share, from $121 million, or $.53 per basic share, year over year. Absent that gain profit rose 29 percent.
Thermo said it had around $214 million in cash and equivalents and $80 million in short-term investments as of Dec. 31.
Looking ahead, Thermo said it expects total revenue in 2006 to grow between 6 percent and 8 percent year over year to between $2.78 billion and $2.83 billion.